Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382651 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT04382651 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 140 participants.
The verdict
NCT04382651, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.
Interventions
- OTHER Placebo
- DRUG MAS825
- DRUG Standard of Care (SoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2021-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04382651
The ClinicalTrials.gov registry entry for NCT04382651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04382651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04382651 about?
NCT04382651 is a clinical study titled "Study of Efficacy and Safety of MAS825 in Patients With COVID-19". This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.
What is the current status of trial NCT04382651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2020-06-11. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT04382651?
The interventions under investigation include: Placebo (OTHER), MAS825 (DRUG), Standard of Care (SoC) (DRUG).
Who is sponsoring clinical trial NCT04382651?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.